After 9 Meters Biopharma announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome, Brookline analyst Kumaraguru Raja said the trial design increases the odds of success given that hitting either of its endpoints can support an NDA filing. Raja reiterates a Buy rating and $74 price target on 9 Meters shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMTR: